A Randomised, Double-blind, Multi-centre Placebo Controlled Trial of Dexmedetomidine for Patients With Agitation and Delirium in the Intensive Care Unit.

Trial Profile

A Randomised, Double-blind, Multi-centre Placebo Controlled Trial of Dexmedetomidine for Patients With Agitation and Delirium in the Intensive Care Unit.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Dexmedetomidine (Primary)
  • Indications Agitation; Delirium
  • Focus Therapeutic Use
  • Acronyms DahLIA
  • Sponsors Hospira
  • Most Recent Events

    • 15 Mar 2016 Primary endpoint has been met. (Ventilator-free hours) as per the results published in the JAMA: the Journal of the American Medical Association
    • 15 Mar 2016 Results published in the JAMA: the Journal of the American Medical Association
    • 18 Jan 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top